We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » BMS Kidney Transplant Drug Nulojix Needs REMS, FDA Says
BMS Kidney Transplant Drug Nulojix Needs REMS, FDA Says
July 15, 2011
Bristol-Myers Squibb’s (BMS) recently approved kidney transplant drug Nulojix will be accompanied by a risk evaluation and mitigation strategy (REMS) for post-transplant lymphoproliferative disorder (PTLD) and progressive multifocal leukoencephalopathy (PML) — both of which can be fatal.